We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPATH.L Regulatory News (PATH)

  • There is currently no data for PATH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Acquisition

7 Jul 2020 14:00

RNS Number : 2917S
Path Investments plc
07 July 2020
 

7 July 2020

Path Investments plc

("Path" or the "Company")

Update on Acquisition of DT Ultravert and Kansas Nitrogen Reserves

 

 

Path Investments plc (TIDM: PATH), the energy and natural resources investment company, is pleased to provide an update on the progress of its agreement with Zoetic International PLC ("Zoetic"), to acquire its 75% ownership of its patented proprietary technology, DT Ultravert ("DTU"), and the acquisition of its Kansas Nitrogen Reserves, its associated leases and equipment (together the "Transaction").

 

Further to the announcement dated 22 June 2020, Path has held a number of discussions with the Financial Conduct Authority ("FCA"). The result of those discussions is that it has been concluded that the Transaction is a reverse takeover under the Listing Rules and the current suspension on the Standard Segment of the Official List and on the Main Market of the London Stock Exchange will continue pending publication of a prospectus. The process of producing the required prospectus is underway and on publication of a prospectus the existing listing will be cancelled and the Ordinary Shares re-admitted to trading ("Readmission").

 

Following further discussions with Zoetic, the consideration for the Transaction has been slightly adjusted. This will now be satisfied by the issue by Path to Zoetic of 15,000,000 warrants to subscribe for ordinary shares in Path at any time from the first to the third anniversaries following completion at an exercise price of 0.75 pence per share, together with 15,000,000 warrants to subscribe for ordinary shares in Path at any time from the first to the third anniversaries following completion at an exercise price of 1.5 pence per share.

 

Additionally, Path has agreed to pay, in perpetuity, to Zoetic a royalty equal to 6% of all gross revenues derived from DTU, accruing from receipt of first revenues, although not payable until 12 months thereafter. Royalty payments will be settled quarterly, with payments being made at the end of the quarter in which Path earns revenue. For the avoidance of doubt, Path has no obligation to make a payment to Zoetic unless it has received the revenue payment from its own customers. Royalty payments due until the fifth anniversary of completion, at Path's discretion, may be settled as to 50 per cent. by the issue of new ordinary shares in Path, in which case the value of those ordinary shares will be based on the volume weighted average price over the 10 business days prior to the date of issue. Thereafter payments due will be settled in cash.

 

Zoetic will enter into an orderly marketing agreement in respect of any exercise of warrants for a period of 12 months from the date of completion which will have been issued as consideration for the Transaction.

 

Completion of the Transaction is expected to occur during the next week, and a further announcement will be made when completion occurs.

 

Commenting, Christopher Theis CEO of Path, said: "We are naturally disappointed by the outcome of our discussions with the FCA, but we are pressing ahead with the preparations for the publication of a prospectus. Meanwhile we look forward to the completion of the Transaction over the coming week and getting to work with our new colleagues in Colorado."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014

 

For further information please contact:

Path Investments plc

C/O IFC

Christopher Theis

 

 

 

IFC Advisory (Financial PR & IR)

020 3934 6630

Tim Metcalfe

 

Zach Cohen

 

 

 

Grant Thornton UK LLC (Financial Adviser)

 

Samantha Harrison

 

Harrison Clarke

020 7383 5100

 

 

 

Keith, Bayley, Rogers & Co. Limited (Broker)

 

Brinsley Holman

07776 30 22 28

Graham Atthill-Beck

07506 43 41 07

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQUBSURRWUBRAR
Date   Source Headline
7th Apr 20227:00 amRNSUpdate on Acquisition
5th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20222:45 pmRNSResult of General Meeting
14th Mar 20221:09 pmRNSPublication of Prospectus, Notice of GM, Fundraise
1st Feb 20227:00 amRNSProposed Transaction Update
31st Dec 20217:00 amRNSProposed Transaction Update
18th Nov 20217:00 amRNSAppointment of Joint Broker
26th Oct 20217:00 amRNSProposed Transaction Update
13th Oct 20216:02 pmRNSCorrection: Holding(s) in Company
13th Oct 20214:52 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSBlock listing Interim Review
29th Sep 20217:00 amRNSInterim Results for the six months to 30 June 2021
28th Sep 20212:45 pmRNSResult of AGM
22nd Sep 20212:41 pmRNSFurther secured loan provided to DG Innovate
9th Sep 20216:01 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSNotice of AGM
18th Aug 202111:54 amRNSCorrection: Holding(s) in Company
18th Aug 20217:00 amRNSHolding(s) in Company
13th Aug 20217:45 amRNSProposed Acquisition of DG Innovate & Suspension
14th Jul 20215:23 pmRNSHolding(s) in Company
14th Jul 20212:39 pmRNSHolding(s) in Company
24th Jun 20217:00 amRNSFinal Results for the Year Ended 31 December 2020
16th Jun 20217:00 amRNSHolding(s) in Company
8th Jun 202111:49 amRNSHolding(s) in Company
7th Jun 202112:04 pmRNSHolding(s) in Company
9th Apr 202110:03 amRNSHolding(s) in Company
9th Apr 20217:00 amRNSBlock Listing
1st Apr 20215:02 pmRNSHolding(s) in Company
31st Mar 20219:55 amRNSTotal Voting Rights
24th Mar 20212:06 pmRNSDirector/PDMR Share Transaction
19th Mar 20218:53 amRNSHolding(s) in Company
12th Mar 20215:36 pmRNSAdmission of previously issued shares
12th Mar 202112:50 pmRNSPublication of Prospectus
8th Mar 202111:05 amRNSSecond Price Monitoring Extn
8th Mar 202111:00 amRNSPrice Monitoring Extension
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:36 pmRNSPrice Monitoring Extension
26th Feb 20212:06 pmRNSSecond Price Monitoring Extn
26th Feb 20212:00 pmRNSPrice Monitoring Extension
26th Feb 20217:00 amRNSEquity Fundraise Update
19th Feb 20217:00 amRNS£3.5 million Equity Fundraise
15th Feb 20212:00 pmRNSTermination of DTU Acquisition
3rd Dec 20209:44 amRNSSubscription for £55,000 of Convertible Loan Stock
5th Nov 20207:00 amRNSFurther re the Acquisition of 75% of DT Ultravert
8th Oct 20209:55 amRNSOption Surrender and Issue of Replacement Options
5th Oct 20207:00 amRNSProposed sale of Kansas Land Leases and equipment
1st Oct 202011:41 amRNSFurther re the Acquisition of DT Ultravert
30th Sep 20207:00 amRNSBoard Changes & Acquisition of Deferred Shares
10th Sep 20201:30 pmRNSInterim Results for the six months to 30 June 2020
10th Sep 20201:15 pmRNSFinal Results for the Year Ended 31 December 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.